Notice of Full Year Results

Destiny Pharma PLC
08 April 2024
 

08 April 2024

 

Destiny Pharma plc

 

("Destiny Pharma" or "the Company")

 

Notice of Full Year Results and Investor Presentation

 

Brighton, United Kingdom - Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, will announce its financial results for the year ended 31 December 2023, on Thursday 25 April 2024.

 

Chris Tovey, Chief Executive Officer, and Shaun Claydon, Chief Financial Officer, will host a briefing for analysts at 8.30am BST followed by a presentation to all existing and potential shareholders at 11:00am BST held via the Investor Meet Company platform. Further details for the analyst briefing will be shared by invitation in due course.

 

Questions can be submitted pre-event via the Investor Meet Company dashboard up until 09:00am BST the day before the meeting, or at any time during the live presentation.

 

Investors can sign up to Investor Meet Company for free, and add to meet Destiny Pharma

plc via: https://www.investormeetcompany.com/destiny-pharma-plc/register-investor

 

Investors who already follow Destiny Pharma plc on the Investor Meet Company platform will automatically be invited.

 

For further information, please contact:

 

Destiny Pharma plc

Chris Tovey, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440

pressoffice@destinypharma.com

 

FTI Consulting

Ben Atwell / Simon Conway / Michael Trace

+44 (0) 203 727 1000

destinypharma@fticonsulting.com

 

Shore Capital (Nominated Advisor and Broker)

Daniel Bush / James Thomas / Lucy Bowden

+44 (0) 207 408 4090

 

About Destiny Pharma

 

Destiny Pharma is an innovative, clinical-stage biotechnology company focused on the development and commercialisation of novel medicines that can prevent life-threatening infections. The company's drug development pipeline includes two late stage assets NTCD-M3, a microbiome-based biotherapeutic for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US, and XF-73 nasal gel, a proprietary drug targeting the prevention of post-surgical staphylococcal hospital infections including MRSA.

 

For further information on the company, please visit www.destinypharma.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings